All eyes are on Tilray (NASDAQ:TLRYfollowing the release of its second quarter financial results on Tuesday (August 28), since — according to a portfolio manager — the company is a leading candidate to an alcohol producer’s entry into the cannabis space.

Doug Waterson, CFO and Portfolio Manager with Faircourt Asset Management and Manager of the Ninepoint UIT Alternative Health Fund told the Investing News Network (INN) a “highly significant portion” of Tilray’s recent gains were due to speculation of the company serving as a partner for the entry of alcohol producer, Diageo plc (NYSE:DEO).

Rumors began swirling following a report citing the entry of the alcohol producer into the cannabis scene, leading to speculation as to which company was closest to any kind of deal–with fingers pointing to Tilray.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

“[Tilray is] a quality name in the space and it would make a good partner for someone looking to enter [like a] beverage company,” Waterson said.

As a result, shares of Tilray increased on Wednesday (August 29) and closed with a 20.64 percent price increase to reach US$62.13. After hours trading brought the company’s share price down 2.54 percent to US$60.55. By Thursday’s (August 30) trading session, the producer’s stock dipped 4.93 percent to reach a closing price of US$58.63.

Waterson added Tilray’s advantage compared to other cannabis names speculated in the race for a deal with Diageo, is its recent relationship to pharmaceuticals and non-exposure into the volatile US cannabis market.

The executive and portfolio manager told INN he thinks investors need to remember this potential deal might not match the famous Constellation Brands (NYSE:STZ) relationship with Canopy Growth (TSX:WEED,NYSE:CGC).

“I think investors should keep in mind that a transaction with a beverage company could take many forms… there are lots of other ways for the companies to work together that might not have that same impact but [can] still be meaningful,” Waterson said. He cautioned investors assuming a rush towards a “controlled position kind of investment.”

Constellation made a second investment into Canopy, adding C$5 billion into the production of the company in international markets. This decision sent cannabis stocks rushing as the markets saw the investment as another sign of maturity for the growing industry.

Waterson said he expects to see the number of deals between cannabis companies and established industries to increase. However, he added those moves won’t be only in Canada, signaling to the global trend of cannabis legalization.

Experts have agreed as the cannabis industry continues growing established markets like pharmaceuticals, tobacco and alcohol would make attempts at entries into the emerging space.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

“I would say it’s more important to [the tobacco industry] to do a deal but it’s also probably more difficult,” Waterson said, citing the political and optics issues entry from tobacco would cause as a potential barrier of entry.

In terms of Tilray’s financial results, Brendan Kennedy, president and CEO of the producer, gave credit to global strategy and a multinational distribution network.

Tilray reported C$12.7 million in revenue for the quarter by selling 1,514 kilograms of cannabis and rising its average net selling price from C$8.12 to C$8.36. The producer also reported a net loss of C$12.8 million.

The company has gained value in the Canadian market as it secured supply agreements for legal adult-use cannabis to BC, Manitoba, Nova Scotia, Ontario, Quebec, Yukon and the Northwest Territories.

Investor takeaway

Tilray made its debut in the public markets earlier this year in July when it launched its initial public offering (IPO). The producer opted for the NASDAQ exchange and offered 10.350 million shares of class 2 common stock at a price of US$17 per share.

Since its launch in the public markets, Tilray’s stock has surged rapidly and so far in the year has increased a whopping 177.49 percent.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the appointment of Marcum LLP (“Marcum”) as its independent registered public accounting firm, effective July 5, 2021 . Marcum was appointed following the resignation of MNP LLP (“MNP”) as the Company’s independent registered public accounting firm effective July 5, 2021 .

“We would like to thank MNP for their guidance and expertise over the past two years and we look forward to working with Marcum as the Company’s new independent registered public accounting firm,” stated Chief Financial Officer, Alex D’Amico.

Keep reading... Show less

Cannabis-infused beverages are not a new product concept, but this summer Canadian drink makers hope consumers will discover them for the first time.

Recreational cannabis beverages have beguiled Canadian producers through different avenues, and many continue to make investments. The promise of these drinks lies in the potential of a more welcoming option for new consumers who may be out of their depth with rolled-up dried flower.

Keep reading... Show less

In the news release, BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years, issued 07-Jul-2021 by BioHarvest Sciences Inc. over PR Newswire, we are advised by the company that an incorrect version of the release was issued inadvertently. The complete, corrected release follows:

BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years

Keep reading... Show less

Trulieve is the first medical cannabis operator to start planting in the state

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today that it commenced operations in West Virginia . The Company has begun cultivation at their 100,000 square foot size facility in Huntington, West Virginia .

Keep reading... Show less

– The Company demonstrates the efficiency and reliability of its BioFarming technology by reducing production cycle time for Cannabis from 14-23 weeks to 3-4 weeks.

– The Company’s BioFarming technology will allow the Company to harvest 13-17 cycles per year versus 2-4 cycles per year for conventional Cannabis agriculture.

Keep reading... Show less